At 7.9% CAGR, Asia Pacific Gastrointestinal Drugs Market is Projected to be Worth US$ 22,377.77 Million by 2031, Says Business Market Insights

According to Business Market Insights' research, the Asia Pacific gastrointestinal drugs market was valued at US$ 12,145.18 in 2023 and is expected to reach US$ 22,377.77 million by 2031, registering a CAGR of 7.9% from 2023 to 2031. Strategic initiatives by companies and increasing research investment for novel drug development and artificial intelligence-based techniques are among the critical factors attributed to the Asia Pacific gastrointestinal drugs market expansion.

Companies operating in the gastrointestinal drugs market constantly focus on strategic developments such as product approvals, collaborations, funding, agreements, and new product launches, which help them improve their sales, increase their geographic reach, and improve their capacities to cater to a greater than existing customer base. A few strategic initiatives taken by key players operating in the gastrointestinal drugs market are mentioned below:

• In September 2023, Vivante Health closed US$ 31 million in a Series B funding round led by Mercato Partners, a new investor, to advance the digital digestive health platform. The new funding is mainly received due to the latest GIThrive platform enhancements that highlight the platform's unique ability to provide proper care at the right time. Series B Capital provides continued technological advancements designed to predict the onset and progression of gastrointestinal conditions and provide complete virtual care.
• In May 2024, Strides Pharma Global Pte. Ltd received approval from the US FDA to market the generic version of Sucralfate Oral Suspension, 1gm/10 mL. The medication is used for the treatment of gastrointestinal diseases such as stomach ulcers, GERD, and stomach inflammation, as well as to help avoid stress ulcers.
• In May 2020, Sanofi, a top manufacturer of brands such as Buscopan for Irritable Bowel Syndrome and Dulcolax for constipation relief, entered the digestive wellbeing market space with the introduction of a new food supplement, Buscobiota. Buscobiota contains three types of Lactobacillus and two types of Bifidobacterium, which can be utilized as a preventive medication for chronic constipation.
• In April 2020, Cara Care collaborated with the Consumer Healthcare Business Unit of Sanofi, Germany, on a holistic approach to digestive health that integrates the availability of Sanofi’s Buscomint bei Reizdarm pharmaceutical drug on Cara Care’s Digital Companion App.

Therefore, strategic initiatives by various companies focusing on the development of drugs for the treatment of digestive diseases are likely to offer growth opportunities to the gastrointestinal drugs market in the coming years.

On the contrary, high cost of biologics hampers the growth of Asia Pacific gastrointestinal drugs market.

Based on drug class, the Asia Pacific gastrointestinal drugs market is segmented into biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants and others. The biologics segment held 27.4% share of the Asia Pacific gastrointestinal drugs market in 2023, amassing US$ 3,331.68 million. It is projected to garner US$ 6,204.37 million by 2031 to expand at 8.1% CAGR during 2023–2031.

By application, the Asia Pacific gastrointestinal drugs market is segmented into irritable bowel syndrome, inflammatory ulcerative colitis, Crohn’s disease, gastroenteritis, celiac disease and others. The irritable bowel syndrome segment held 30.5% share of the Asia Pacific gastrointestinal drugs market in 2023, amassing US$ 3,707.92 million. It is projected to garner US$ 7,015.95 million by 2031 to expand at 8.3% CAGR during 2023–2031.

By route of administration, the Asia Pacific gastrointestinal drugs market is bifurcated into oral and parenteral. The oral segment held 67.8% share of the Asia Pacific gastrointestinal drugs market in 2023, amassing US$ 8,229.56 million. It is projected to garner US$ 15,695.46 million by 2031 to expand at 8.4% CAGR during 2023–2031.

By distribution channel, the Asia Pacific gastrointestinal drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held 49.9% share of the Asia Pacific gastrointestinal drugs market in 2023, amassing US$ 6,058.78 million. It is projected to garner US$ 11,552.03 million by 2031 to expand at 8.4% CAGR during 2023–2031.

Based on country, the Asia Pacific gastrointestinal drugs market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 29.9% share of Asia Pacific gastrointestinal drugs market in 2023, amassing US$ 3,634.35 million. It is projected to garner US$ 6,954.48 million by 2031 to expand at 8.5% CAGR during 2023–2031.

Key players operating in the Asia Pacific gastrointestinal drugs market are Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, and Pfizer Inc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com